2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, LGL, Hodgkin Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4330 Clinical and preanalytical determinants of successful hair bulb-derived germline DNA testing in hematologic malignancies

Ferran Balbastre-Úbeda, MS, Sara Torres-Esquius, CGC2, Maria Gabarrós-Subirà3, Francisco Beas, MD4, Jordi Leno-Colorado, PhD5, Ana Maria Garrido6, Pamela Acha, PhD7, Adoracion Blanco, PhD8, David Valcarcel, MD, PhD9, Maria Julia Montoro, MD, PhD10, Andres Jerez, MD, PhD11
1 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
2 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
3 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
4 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
5 Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain
6 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
7 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
8 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
9 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
10 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain
11 Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

Introduction

Identification of germline predisposition variants is increasingly important for clinical decision-making in hematologic neoplasms (HNs). Although cultured skin fibroblasts remain the gold-standard non-hematopoietic source of germline DNA, their prolonged turnaround times limits routine use. Hair bulbs have recently emerged as a rapid and practical alternative. However, evidence-based recommendations regarding specimen collection, quality control and sequencing performance remain lacking. We aimed to identify the clinical and preanalytical determinants of successful hair bulb-derived DNA acquisition and provide practical guidance for its routine implementation in germline testing for HNs.

Methods

Hair bulbs were collected from patients undergoing germline testing for suspected hereditary HNs as part of routine clincial care. DNA quantity, purity and integrity were assessed using Qubit fluorimetry, NanoDrop spectrophotometry, and microfluidic electrophoresis, respectively, with DNA integrity reported as the DNA Integrity Number (DIN). Library preparation was performed using the KAPA Hyper Exome V2 probes and sequenced on a NovaSeq 6000 platform. Whole-exome sequencing (WES) quality metrics included average sequencing depth, on-target reads, median insert size and duplicate reads.

Results

A total of 111 hair bulb-derived DNA samples were evaluated, without imputation of missing data. Thirty-one patients received chemotherapy within the 6 months preceding specimen collection and were included in the analysis of chemotherapy effects. Sensitivity analyses identified day 6 after chemotherapy initiation as the earliest timepoint associated with reduced DNA yield and approximately day 50 after treatment cessation as the earliest evidence of yield recovery. Hair bulbs collected within this time window yielded ~7.5-fold less DNA than chemotherapy-naïve samples (median, 8.4 vs 63.1 ng/µL; p < 0.001).

Among patient-related variables, only sex influenced hair bulb DNA yield, with male-derived samples yielding higher DNA concentrations than female-derived samples (72.6 vs 51.1 ng/µL; p=0.007). In contrast, neither patient age (Spearman ρ=0.116; p=0.260) nor the presence of telomere biology disorders (63.7 vs 61.4 ng/µL; p=0.818) affected DNA yield.

Regarding preanalytical variables, prolonged storage of extracted DNA at -20ºC was only associated with a slight decline in molecular integrity. Although DIN showed slight time-dependent decline (β=-0.016; p=0.023), no meaningful deterioration was observed after stratification into storage intervals. Samples with the longest storage times (median 32.8 months) retained a median DIN of 6.9, demonstrating the suitability of long-term frozen storage.

Hair bulb DNA consistently achieved high-quality extraction metrics, with a median DNA yield of 63.1 ng/µL (IQR 34.6–116.3), median A260/280 of 2.06 (2.04-2.08), median A260/230 of 1.77 (1.52-1.87), and median DIN of 7.3 (6.8-7.6). Overall WES performance was likewise consistently high, with a median sequencing depth of 61.9x (55.1-83.7), median on-target reads of 82.8% (82.2-83.8), median insert size of 134.5 bp (119.3-142.5), and median duplicate reads of 21.4% (19.8-25.4). These values may represent practical reference benchmarks for laboratories implementing hair bulb-derived germline testing.

Overall, 98.9% of samples provided sufficient DNA input (≥100ng) for WES library preparation. Once this requirement was met, no DNA purity or integrity metric independently predicted WES performance. Likewise, RNA carryover, estimated from the discrepancy between NanoDrop and Qubit measurements, showed no measurable impact on any sequencing quality parameter. Only a modest positive association was observed between A260/230 and mean sequencing depth (R²=0.14; β=32.0; p=0.032).

Conclusions

Hair bulb-derived DNA proved highly robust to most clinical variables, supporting its implementation as a routine source for germline testing in HNs. Hair should be collected before chemotherapy or within the first week after treatment initiation, whereas prolonged frozen storage does not compromise sequencing suitability. DNA quantity emerged as the principal determinant of WES suitability, while purity and integrity metrics contributed little additional predictive value. Together, these findings provide an evidence-based implementation framework for adopting hair bulbs as the preferred first-line source of germline DNA in HNs.

Ferran Balbastre-Úbeda, MS: No relevant conflicts of interest to declare.